A novel subtype of sporadic Creutzfeldt-Jakob disease with PRNP codon 129MM genotype and PrP plaques.

"Declarations Conflict of interestB.S. Appleby has received research funding from CDC, NIH, Ionis, and Alector. He is consultant for Acadia, Ionis, Sangamo, and Merck. Received royalties from Wolters Kluwer. Drs. Orru’ and Caughey have submitted patent applications relating to RT-QuIC assays. All the other authors declare that they have no competing interests. Ethics approval and consent to participateAll procedures were conducted under protocols approved by the Institutional Review Board at CWRU. In all cases, written informed consent for research was obtained from the patient or legal guardian and the material used had appropriate ethical approval for use in this study. All patient data and samples were coded and handled according to NIH guidelines to protect patient identities. Animal studies were performed under the protocols approved by CWRU Institutional Animal Care and Use Committee (IACUC). Conflict of interest B.S. Appleby has received research funding from CDC, NIH, Ionis, and Alector. He is consultant for Acadia, Ionis, Sangamo, and Merck. Received royalties from Wolters Kluwer. Drs. Orru’ and Caughey have submitted patent applications relating to RT-QuIC assays. All the other authors declare that they have no competing interests."

"Funding This study was supported by National Institutes of Health (K99/R00 AG068359) and CJD Foundation Grants to I. Cali. This work was partially supported by CDC Grant (NU38CK000480) and NIAID P01AI077774."